The theme of the current PPG is the study of lipoproteins and atherosclerosis in induced mutant mice, with the main focus on understand apolipoprotein and lipoprotein processing gene function through the use of various transgenic and knockout models. Scientific knowledge gathered in the last 5 years now makes it possible to ask deep questions related to genes and pathways controlling atherosclerotic lesion formation and progression, macrophage cholesterol and phospholipid metabolism, cholesterol regulation of gene transcription, and the particular role of HDL and the lipid transfer protein proteins that regulate HDL levels in atherogenesis. We believe that this new knowledge will allow the achievement of the theme of the proposed PPG, which is the identification of new genes and pathways involved in cholesterol homeostasis and atherosclerosis. The investigators involved in the proposed PPG are on the faculties of two of New York's leading research universities, Rockefeller and Columbia. The PI, Drs. Breslow, and the co- PI, Dr. Tall, metabolism and atherogenesis. They are joined in this effort by 2 very talented mid-career faculty, Drs. Tabas and Smith, who both share interests in macrophage biology and the role of the macrophage in atherosclerosis. Three cores are proposed: a continuation of the transgenic and knockout mouse core headed by Dr. Walsh, a new gene expression profiling core headed by Dr. Swergold, and an administrative core. The projects entail studying: 1) atherosclerosis susceptibility genes in the mouse (Breslow-RU), 2) macrophage death and lipid metabolism in atherosclerosis (Tabas-Columbia), 3) regulation and function of lipid transfer proteins (Tall-Columbia), 4) macrophage lipid uptake, efflux and atherosclerosis (Smith-RU-subcontract Tall-Columbia). All of these projects are consonant with the theme of the PPG and will make extensive use of the transgenic animal core for the creation of transgenic animal core for the creation of transgenic and knockout mice and cryopreservation of important strains. Moreover, a new expression profiling core is proposed which will utilize new array technology to assess changes in gene expression; this approach will be combined with linkage analysis to aid in the discovery of new atherosclerosis susceptibility genes and will also be used to identify new target genes that are up-regulated by sterols, cAMP or apoptosis in macrophages. These studies are likely to contribute important new information relevant to human atherosclerosis that may lead to new diagnostic methods or therapies

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Program Projects (P01)
Project #
2P01HL054591-06
Application #
6159401
Study Section
Heart, Lung, and Blood Initial Review Group (HLBP)
Project Start
1995-07-15
Project End
2005-06-30
Budget Start
2000-07-01
Budget End
2001-06-30
Support Year
6
Fiscal Year
2000
Total Cost
$1,609,435
Indirect Cost
Name
Rockefeller University
Department
Psychology
Type
Other Domestic Higher Education
DUNS #
071037113
City
New York
State
NY
Country
United States
Zip Code
10065
Fredman, Gabrielle; Kamaly, Nazila; Spolitu, Stefano et al. (2015) Targeted nanoparticles containing the proresolving peptide Ac2-26 protect against advanced atherosclerosis in hypercholesterolemic mice. Sci Transl Med 7:275ra20
Libby, Peter; Tabas, Ira; Fredman, Gabrielle et al. (2014) Inflammation and its resolution as determinants of acute coronary syndromes. Circ Res 114:1867-79
Subramanian, Manikandan; Tabas, Ira (2014) Dendritic cells in atherosclerosis. Semin Immunopathol 36:93-102
Subramanian, Manikandan; Hayes, Crystal D; Thome, Joseph J et al. (2014) An AXL/LRP-1/RANBP9 complex mediates DC efferocytosis and antigen cross-presentation in vivo. J Clin Invest 124:1296-308
Nagareddy, Prabhakara R; Murphy, Andrew J; Stirzaker, Roslynn A et al. (2013) Hyperglycemia promotes myelopoiesis and impairs the resolution of atherosclerosis. Cell Metab 17:695-708
Subramanian, Manikandan; Thorp, Edward; Hansson, Goran K et al. (2013) Treg-mediated suppression of atherosclerosis requires MYD88 signaling in DCs. J Clin Invest 123:179-88
Gautier, Emmanuel L; Westerterp, Marit; Bhagwat, Neha et al. (2013) HDL and Glut1 inhibition reverse a hypermetabolic state in mouse models of myeloproliferative disorders. J Exp Med 210:339-53
Rodríguez, José M; Wolfrum, Susanne; Robblee, Megan et al. (2013) Altered expression of Raet1e, a major histocompatibility complex class 1-like molecule, underlies the atherosclerosis modifier locus Ath11 10b. Circ Res 113:1054-64
Tabas, Ira; Glass, Christopher K (2013) Anti-inflammatory therapy in chronic disease: challenges and opportunities. Science 339:166-72
Rong, James X; Blachford, Courtney; Feig, Jonathan E et al. (2013) ACAT inhibition reduces the progression of preexisting, advanced atherosclerotic mouse lesions without plaque or systemic toxicity. Arterioscler Thromb Vasc Biol 33:4-12

Showing the most recent 10 out of 124 publications